MetrioPharm develops drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of preventing diseases of aging. Our drug candidates have shown the potential to be safer and more tolerable than existing therapies. MP1032 is currently in clinical Phase II.
Products, services, technology
Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.
Cooperation possibilities
Licensing, strategic partnerships, investments
- https://metriopharm.com
- +41 44 515 21 97
- info@metriopharm.com
- Eva Brysch
